Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Pericarditis IV: Nursing Management01:25

Pericarditis IV: Nursing Management

Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simultaneous Laparoscopic Repair of Iatrogenic Lumbar and Inguinal Hernias Using Combined TAPP and IPOM: A Case Report.

The Tokai journal of experimental and clinical medicine·2026
Same author

Automated Compactness Quantitative Metrics for Wrist Bone on Conventional Radiography in Rheumatoid Arthritis: A Clinical Evaluation Study.

Journal of imaging·2026
Same author

Clinical outcomes of third-line chemotherapy prior to best supportive care in patients with stage IV colorectal cancer: a single-center study from Japan.

Journal of gastrointestinal oncology·2025
Same author

Successful Laparoscopic-Assisted Pancreaticoduodenectomy for a Neuroendocrine Tumor of the Papilla of Vater in Type 1 Portal Annular Pancreas.

Surgical case reports·2025
Same author

Is radix ligation of the inferior mesenteric artery effective in Japanese-Style D3 radical lymph node dissection for sigmoid colon and rectal cancer surgery?-a single-center retrospective analysis since 2002.

Journal of gastrointestinal oncology·2025
Same author

Intraduodenal wall recurrence 11 years after distal pancreatectomy for pancreatic ductal adenocarcinoma.

Clinical journal of gastroenterology·2025

Related Experiment Video

Updated: Jul 13, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

[Management for TNF failure].

Masaya Mukai1

  • 1Division of Rheumatology and Hematology, Department of Medicine, Sapporo City General Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 24, 2007
PubMed
Summary

Biologic therapies, including anti-tumor necrosis factor (TNF) agents, have revolutionized rheumatoid arthritis (RA) treatment. New biologics targeting other pathways offer hope for patients refractory to current RA therapies.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) treatment has been significantly advanced by the introduction of biologic agents.
  • Anti-tumor necrosis factor (TNF) therapies (infliximab, etanercept, adalimumab) have demonstrated revolutionary efficacy in RA management.
  • A subset of RA patients remains refractory to anti-TNF therapy, necessitating alternative treatment strategies.

Purpose of the Study:

  • To review the current landscape of biologic therapies for rheumatoid arthritis.
  • To highlight emerging biologic agents targeting different pathways for RA treatment.
  • To discuss the future potential of personalized medicine in RA management based on predictive values.

Main Methods:

  • Literature review of clinical trials and studies on biologic agents for rheumatoid arthritis.

Related Experiment Videos

Last Updated: Jul 13, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

  • Analysis of treatment outcomes for patients with RA, including those refractory to anti-TNF agents.
  • Exploration of novel therapeutic targets and predictive biomarkers in RA.

    • Main Results:

    • Anti-TNF agents have transformed RA treatment, but treatment failure occurs in some patients.
    • Emerging biologics targeting CTLA4 (abatacept), IL-6 (tocilizumab), and CD20 (rituximab) show promise for anti-TNF refractory RA.
    • These novel agents are expected to provide effective alternatives for patients with inadequate response to current therapies.

    Conclusions:

    • The evolution of biologic therapies offers expanding options for rheumatoid arthritis management.
    • Future RA treatment paradigms will likely involve selecting therapies based on individual patient profiles and predictive markers.
    • Continued research into novel targets and personalized approaches is crucial for optimizing RA patient outcomes.